Clinical trial
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1…
NCT00294372 · Boehringer Ingelheim, Industry · Terminated
Key facts
| NCT number | NCT00294372 |
|---|---|
| Title | Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients |
| Official title | Randomised, Double-blind, Placebo-controlled 7 Day Monotherapy Phase IIa Study to Evaluate the Antiviral Activity and Safety of Increasing Doses of Oral Administered RTV-boosted BILR 355 BS (75 mg and 150 mg Twice Daily) in HIV-1-infected, NNRTI-experienced Patients, Followed by 28 Day Combination… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | BILR 355 BS, Placebo |
| Enrollment | 36 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2007 |
| First posted | Feb 22, 2006 |
| Last update posted | Nov 14, 2013 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: